In this short interview from SLAS 2025 in San Diego, Semarion CEO Jeroen Verheyen shares how Semarion is solving key bottlenecks in in vitro drug discovery.

Semarion is pioneering a new materials platform to accelerate the generation of high-quality biological data. Using our proprietary SemaCyte® microcarriers, we transform adherent cells into barcoded, mobile reagents—enabling faster, more reproducible, and automated cell assays.

In this video, Jeroen discusses:
– The current challenges in adherent cell assays
– How Semarion’s technology boosts data throughput and assay standardization
– How we support the AI-driven, automated drug discovery revolution
– Our recent recognition with the SLAS New Product Award 2025